News – Page 1100 – Endpoints News

Latest testimony in Shkreli trial centers on a Retrophin stock deal gone sour

8 years ago

Researchers plot a course into PhIII after another Alzheimer’s drug flunks a key test

8 years ago

BIO lobbies lawmakers for new rules that expose biotech short sellers

8 years ago

Biotech M&A? Novartis chief Jimenez says he’s sticking to the under-$1B aisle for now

8 years ago

Vertex shares shoot up, adding $8B in market cap after cystic fibrosis triples 'knocked it out of the park'

8 years ago

FDA OKs a new triple hep C drug from Gilead -- plus the top 10 anti-viral companies in the world

8 years ago

Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab

8 years ago

Takeda shifting hundreds of R&D staffers to Boston — report; Shire inks hemophilia deal; Amgen, Array partner on ...

8 years ago

BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta

8 years ago

Paratek goes 3-for-3 in PhIII, but antibiotic stumbles on side effect profile

8 years ago

Back from the dead: Nektar hunts a blockbuster deal as opioid '181 looks less addictive than oxy

8 years ago

Clarus readies a slate of big PhIII risk-sharing bets with a new $910M fund

8 years ago

King cancer: The top 10 therapeutic areas in biopharma R&D

8 years ago

Puma wins big FDA OK for neratinib after running the gamut with investors

8 years ago

Strongbridge raises $53M in financing; Sienna Bio sets terms for $70M IPO

8 years ago

CymaBay shares get a bounce on positive PBC PhII data

8 years ago

FDA's Scott Gottlieb is fielding a new team of recruiters to start scouting top talent

8 years ago

FDA embraces the first US application for a gene therapy, offering an accelerated test case

8 years ago

FDA keeps a firm grip on partial hold for troubled Repros Therapeutics, with big trial demand

8 years ago

FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO

8 years ago

Pascal Soriot is staying at AstraZeneca after all, confirming upcoming presentation - reports

8 years ago

Akcea IPO stumbles and falls well below the range, but still raises $175M

8 years ago

Jackie Fouse gets back into biopharma as executive chairman of Dermavant; Ex-GSK chief Andrew Witty joins a biotech ...

8 years ago

Mylan, Amgen score unanimous AdComm backing for Roche copycats; Alder raises $161M

8 years ago

First page Previous page 1097 1098 109911001101 1102 1103 Next page Last page